No­vo Nordisk forms car­diometa­bol­ic drug dis­cov­ery ac­cel­er­a­tor to get to re­search faster

No­vo Nordisk is now tap­ping in­to ear­li­er stages of car­diometa­bol­ic re­search by bring­ing to­geth­er aca­d­e­m­ic in­sti­tu­tions and Ger­man drug dis­cov­ery shop Evotec af­ter it bought a cou­ple of star­tups and inked mul­ti­ple biotech col­lab­o­ra­tions this sum­mer.

Fol­low­ing a chron­ic kid­ney dis­ease tie-up in 2020, the Dan­ish Big Phar­ma and Evotec are com­ing to­geth­er again to form a trans­la­tion­al drug dis­cov­ery ac­cel­er­a­tor dubbed LAB eN². It’s named af­ter the com­pa­nies’ ini­tials and is a joint col­lab­o­ra­tion be­tween Evotec and No­vo’s Bio In­no­va­tion Hub, an ex­ter­nal in­no­va­tion unit of the phar­ma based in Cam­bridge, MA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER